Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29787276 | 0.94 | KMT2A (0.43) | KMT2AMEN1MAPTHSD17B10TSHR | |
| SCHEMBL23214292 | 0.84 | LMNA (0.49) | KMT2AMAPTHSD17B10NPSR1ALDH1A1 | |
| SCHEMBL741624 | 0.83 | GAA (0.40) | KMT2AMEN1MAPTHSD17B10TSHR | |
| SCHEMBL4598011 | 0.81 | KMT2A (0.44) | KMT2AMEN1MAPTHSD17B10TSHR | |
| SCHEMBL1540028 | 0.81 | ALDH1A1 (0.49) | KMT2AMEN1MAPTHSD17B10TSHR | |
| SCHEMBL1444863 | 0.79 | GPR35 (0.38) | KMT2AMEN1TSHRALDH1A1L3MBTL1 | |
| SCHEMBL1921091 | 0.77 | ALDH1A1 (0.49) | KMT2AMAPTHSD17B10NPSR1ALDH1A1 | |
| SCHEMBL622999 | 0.77 | HSD17B10 (0.47) | KMT2AMEN1MAPTHSD17B10TSHR | |
| SCHEMBL560326 | 0.76 | RAB9A (0.51) | KMT2AMEN1MAPTHSD17B10TSHR | |
| SCHEMBL8149166 | 0.74 | TRPM8 (0.45) | KMT2AMEN1MAPTHSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540134-B2 | Inhibitors of adrenoreceptor ADRAC2 | BAYER AKTIENGESELLSCHAFT (DE) | 2026-02-03 | — | — | US | disclosed |
| CN-120136863-A | Adrenergic receptor ADRAC2 antagonists | 拜耳公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-120025328-A | Adrenergic receptor ADRAC2 antagonists | 拜耳公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-120025327-A | Adrenergic receptor ADRAC2 antagonists | 拜耳公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-114929694-B | Adrenergic receptor ADRAC2 antagonists | 拜耳公司 | 2025-02-07 | — | — | CN | disclosed |
| US-20240000767-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2024-01-04 | — | — | US | disclosed |
| EP-4175954-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2023-05-10 | — | — | EP | disclosed |
| CN-116057057-A | Conjugates of alpha 2-adrenoceptor subtype C (alpha-2C) antagonists and TASK1/3 channel blockers for the treatment of sleep apnea | 拜耳公司 | 2023-05-02 | — | — | CN | disclosed |
| US-20230115270-A1 | INHIBITORS OF ADRENORECEPTOR ADRAC2 | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| CN-114929694-A | Adrenergic receptor ADRAC2 antagonists | 拜耳公司 | 2022-08-19 | — | — | CN | disclosed |
| EP-4021905-A1 | INHIBITORS OF ADRENORECEPTOR ADRAC2 | Bayer Aktiengesellschaft (DE) | 2022-07-06 | — | — | EP | disclosed |
| WO-2022008426-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2022-01-13 | — | — | WO | disclosed |
| EP-2226322-B1 | IMIDAZOLE CARBONYL COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2015-01-21 | — | — | EP | disclosed |
| US-8927588-B2 | Imidazole carbonyl compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-01-06 | — | — | US | disclosed |
| US-20140073622-A1 | IMIDAZOLE CARBONYL COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-03-13 | — | — | US | disclosed |
| US-8536197-B2 | Imidazole carbonyl compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-09-17 | — | — | US | disclosed |
| US-20100311966-A1 | IMIDAZOLE CARBONYL COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-12-09 | — | — | US | disclosed |
| EP-2226322-A1 | IMIDAZOLE CARBONYL COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2010-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240000767-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | ADRA2C, ADRB2, CHRNA2 | KMT2A 1198/4885MEN1 4047/4885MAPT 4557/4885 |
| US-12540134-B2 | Inhibitors of adrenoreceptor ADRAC2 | ADRA2C, ADRB3, ADRB2 | KMT2A 3674/4885MEN1 3849/4885MAPT 3419/4885 |
| US-20230115270-A1 | INHIBITORS OF ADRENORECEPTOR ADRAC2 | ADRA2C, ADRB2, ADRB3 | KMT2A 2828/4885MEN1 3988/4885MAPT 3024/4885 |
| US-20100311966-A1 | IMIDAZOLE CARBONYL COMPOUND | TOP1, TOP2B, TOP2A | KMT2A 847/4885MEN1 3960/4885MAPT 1455/4885 |
| US-20140073622-A1 | IMIDAZOLE CARBONYL COMPOUND | TOP1, TOP2B, TOP2A | KMT2A 1335/4885MEN1 3629/4885MAPT 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.